ClinicalTrials.gg
RecruitingNCT03593408Updated Oct 23, 2026

Pharmacokinetics of Sedatives and Analgesics During Extracorporeal Membrane Oxygenation (ECMO) Support

An observational study in Drug Effect, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 0 Days to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Boston Children's Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
0 Days to 17 Years
Sex
All
01

Study summary

This study will measure plasma concentrations of dexmedetomidine, fentanyl, morphine and midazolam in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to understand the pharmacokinetics of these drugs in this setting.

02

Conditions studied

  • Drug Effect
03

In context

Lead sponsor

Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All pediatric patients who present to Boston Children's Hospital (BCH) and supported on ECMO and receiving one or a combination of the following drugs dexmedetomidine, fentanyl, midazolam or morphine as part of the sedation management.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • supported on ECMO
  • receiving one or a combination of the following drugs dexmedetomidine, fentanyl, midazolam or morphine as part of sedation management

Exclusion criteria

Exclusion Criteria:

-none

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric Patients on ECMO Support

    Drug: Dexmedetomidine · Drug: Fentanyl · Drug: Midazolam · Drug: Morphine

Interventions

  • Administered for sedation management per hospital protocol

  • Administered for sedation management per hospital protocol

  • Administered for sedation management per hospital protocol

  • Administered for sedation management per hospital protocol

06

What researchers measure

Primary outcomes

  1. Change in plasma concentrations of dexmedetomidine

    Time frame: Throughout the duration of sedation management with dexmedetomidine at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped

  2. change in plasma concentrations of fentanyl

    Time frame: Throughout the duration of sedation management with fentanyl at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped

  3. change in plasma concentrations of morphine

    Time frame: Throughout the duration of sedation management with morphine at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped

  4. change in plasma concentrations of midazolam

    Time frame: Throughout the duration of sedation management with midazolam at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped

07

Study locations

1 of 1 sites recruiting
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Viviane Nasr, MD · Contact
    • Viviane Nasr, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2019 (actual). Primary completion is estimated for Aug 2027, 101 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Aug 2026 → Aug 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2018
First posted
Jul 20, 2018
StartActual
Feb 8, 2019
Primary completionEst.
Aug 1, 2027was Aug 2026
CompletionEst.
Dec 1, 2027was Dec 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 1, 2026→Aug 1, 2027
Oct 23, 2026
Study completion
Dec 1, 2026→Dec 1, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Aug 1, 2026→Aug 1, 2027
    Study completion Dec 1, 2026→Dec 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03593408
Responsible party
Viviane Nasr (Cardiac Anesthesiologist, Boston Children's Hospital) — Principal investigator
First posted
Jul 20, 2018
Start date
Feb 8, 2019
Primary completion
Aug 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Viviane Nasr, MD
Contact
viviane.nasr@childrens.harvard.edu
617-355-6225
Viviane Nasr, MD
principal investigator · Boston Children's Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion